scholarly article | Q13442814 |
P50 | author | Mohummad Minhaj Siddiqui | Q37831177 |
Soroush Rais-Bahrami | Q40114897 | ||
Bradford J. Wood | Q40114938 | ||
Nabeel A Shakir | Q50652518 | ||
Baris Turkbey | Q88769455 | ||
Peter L Choyke | Q90059714 | ||
Peter A Pinto | Q90059716 | ||
Arvin K George | Q96240193 | ||
Lambros Stamatakis | Q97527341 | ||
Maria J Merino | Q107749611 | ||
Jason T. Rothwax | Q114421919 | ||
Chinonyerem Okoro | Q114421920 | ||
Dima Raskolnikov | Q114421921 | ||
Annerleim Walton-Diaz | Q114421922 | ||
P2093 | author name string | Richard Simon | |
Daniel Su | |||
P2860 | cites work | Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies | Q27001055 |
Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group | Q30054617 | ||
Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy | Q33605381 | ||
NCCN clinical practice guidelines in oncology: prostate cancer early detection | Q34616553 | ||
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging | Q35202301 | ||
Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging | Q35354750 | ||
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? | Q36946494 | ||
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies | Q37149144 | ||
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? | Q37280719 | ||
Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen | Q37381526 | ||
Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer | Q37439227 | ||
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance | Q37689254 | ||
Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. | Q37937948 | ||
Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. | Q38180533 | ||
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer | Q39391979 | ||
Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? | Q39601468 | ||
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial | Q39752227 | ||
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer | Q40114843 | ||
Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers | Q40183239 | ||
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. | Q45967722 | ||
Pathological outcomes of candidates for active surveillance of prostate cancer | Q46511086 | ||
Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. | Q53304507 | ||
Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis | Q81036362 | ||
Negative predictive value for cancer in patients with "gray-zone" PSA level and prior negative biopsy: preliminary results with multiparametric 3.0 Tesla MR | Q84253472 | ||
P4510 | describes a project that uses | magnetic resonance imaging | Q161238 |
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | prostate cancer | Q181257 |
biopsy | Q179991 | ||
P304 | page(s) | 1642-1648 | |
P577 | publication date | 2014-08-09 | |
P1433 | published in | Journal of Urology | Q15709979 |
P1476 | title | Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy | |
P478 | volume | 192 |
Q42321987 | 1.5-Tesla Multiparametric-Magnetic Resonance Imaging for the detection of clinically significant prostate cancer |
Q38823661 | A urologist's perspective on prostate cancer imaging: past, present, and future |
Q57317620 | Author Reply |
Q26774839 | Current role of multiparametric magnetic resonance imaging for prostate cancer |
Q41690642 | Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance? |
Q53111203 | Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. |
Q53887860 | Improved biopsy efficiency with MR/ultrasound fusion-guided prostate biopsy. |
Q35820198 | Is magnetic resonance/ultrasound fusion prostate biopsy better than systematic prostate biopsy? An updated meta- and trial sequential analysis |
Q52624219 | MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? |
Q38545811 | MRI-guided biopsies and minimally invasive therapy for prostate cancer |
Q39129035 | Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10. |
Q37055000 | Magnetic Resonance Imaging-Ultrasound Fusion-Guided Prostate Biopsy: Review of Technology, Techniques, and Outcomes |
Q36123058 | Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients |
Q40899372 | Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights |
Q38377827 | Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy |
Q39174624 | Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy |
Q34177428 | Multiparametric MRI in the PSA screening era |
Q28081873 | Multiparametric-MRI in diagnosis of prostate cancer |
Q38524498 | Optimizing Patient Population for MP-MRI and Fusion Biopsy for Prostate Cancer Detection |
Q38753426 | PI-RADSv2: How we do it. |
Q38843182 | Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers |
Q52741581 | Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases. |
Q57107304 | The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points |
Q53634864 | The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy. |
Q30988469 | The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy |
Q91705711 | The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance |
Q38504909 | The role of MRI in active surveillance for prostate cancer |
Q38746242 | The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. |
Q53589252 | Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. |
Search more.